NCT00092014 - A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211) | Biotech Hunter

Enrollment

1,053

Participants

Timeline

Start Date

September 1, 2002

Primary Completion Date

April 1, 2004

Study Completion Date

April 1, 2004

Conditions

Postmenopausal Osteoporosis

Interventions

DRUG

Alendronate

Alendronate sodium, 70 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.

DRUG

Risedronate 35 mg

Risendronate, 35 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.

DIETARY_SUPPLEMENT

Elemental Calcium

Elemental calcium at least 1,000 mg daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.

DIETARY_SUPPLEMENT

Vitamin D

Vitamin D at least 400 international units daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.

DRUG

Risendronate placebo

Risendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.

DRUG

Alendronate placebo

Alendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.

All Listed Sponsors

lead

Organon and Co

INDUSTRY